# Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil

Source: https://onco.cc/trials/nct07353268/  
OnCo record `nct07353268` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of QL1706 and fruquintinib in colorectal cancer, run by Tao Zhang, not yet recruiting.

## Summary

Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. is a phase 2, randomised interventional study registered as NCT07353268 by Tao Zhang, with a registry enrolment figure of 76 participants, started 2026-01-21 and due to reach its primary completion in 2027-08-31. Interventions recorded: QL1706 + Fruquintinib + Short-Course Ablative Radiotherapy (SCART); Standard Third-Line Therapy. Conditions listed: Colorectal Cancer. Primary outcome: Progression Free Survival（PFS）. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic colorectal cancer with unresectable liver metastasis(es) measuring ≥5 cm in the longest diameter". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07353268
- Phase: 2
- Setting: A Phase Ib/II Study Evaluating the Safety, Tolerability, and Efficacy of Epalolitovoreli Monoclonal Antibody (QL1706) and Fruquintinib Combined With Short-Course Radiotherapy (SCRT) Versus Standard Third-Line Therapy in Patients With Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer.
- Sponsor: Tao Zhang
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT07353268: https://clinicaltrials.gov/study/NCT07353268

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [QL1706](https://onco.cc/drugs/ql1706/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07353268.json